Cognition Therapeutics (NASDAQ:CGTX) Rating Increased to Strong-Buy at Brookline Capital Management

Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTX) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

Several other research analysts have also recently issued reports on the stock. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research report on Thursday, December 19th. Finally, HC Wainwright boosted their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Trading Down 5.8 %

Shares of NASDAQ:CGTX opened at $0.71 on Monday. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The company has a market cap of $29.50 million, a PE ratio of -0.73 and a beta of 0.95. The company’s 50 day moving average is $0.59 and its 200 day moving average is $0.70.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors have recently modified their holdings of CGTX. Mercer Global Advisors Inc. ADV boosted its position in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares in the last quarter. Sigma Planning Corp lifted its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Cognition Therapeutics in the 4th quarter valued at $26,000. Finally, Virtu Financial LLC purchased a new stake in Cognition Therapeutics in the 3rd quarter worth $27,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.